Regorafenib Plus Vincristine and Irinotecan in Pediatric Patients With Recurrent/Refractory Solid Tumors: An Innovative Therapies for Children With Cancer Study
CONCLUSIONS: Regorafenib can be combined sequentially with standard dose VI in pediatric patients with relapsed/refractory solid tumors with appropriate dose modifications. Clinical activity was observed in patients with RMS and EWS (clinicaltrials.gov NCT02085148).PMID:37606641 | DOI:10.1158/1078-0432.CCR-23-0257 (Source: Cancer Control)
Source: Cancer Control - August 22, 2023 Category: Cancer & Oncology Authors: Michela Casanova Francisco Bautista Quentin Campbell Hewson Guy Makin Lynley V Marshall Arnauld C Verschuur Adela Ca ñete Nieto Nadege Corradini Bart A Ploeger Barbara J Brennan Udo Mueller Hong Zebger Gong John W Chung Birgit Geoerger Source Type: research
METTL3-modified lncRNA-MALAT1 regulates the molecular axis of miR-124-3p/CDK4 involved in Ewing's sarcoma
In conclusion, METTL3 promotes tumorigenesis of ES through the MALAT1/miR-124-3p/CDK4 axis.PMID:37605570 | DOI:10.14715/cmb/2023.69.6.29 (Source: Cellular and Molecular Biology)
Source: Cellular and Molecular Biology - August 22, 2023 Category: Molecular Biology Authors: Fangzhou He Tingting Ren Xiaodong Tang Source Type: research
METTL3-modified lncRNA-MALAT1 regulates the molecular axis of miR-124-3p/CDK4 involved in Ewing's sarcoma
In conclusion, METTL3 promotes tumorigenesis of ES through the MALAT1/miR-124-3p/CDK4 axis.PMID:37605570 | DOI:10.14715/cmb/2023.69.6.29 (Source: Mol Biol Cell)
Source: Mol Biol Cell - August 22, 2023 Category: Molecular Biology Authors: Fangzhou He Tingting Ren Xiaodong Tang Source Type: research
Regorafenib Plus Vincristine and Irinotecan in Pediatric Patients With Recurrent/Refractory Solid Tumors: An Innovative Therapies for Children With Cancer Study
CONCLUSIONS: Regorafenib can be combined sequentially with standard dose VI in pediatric patients with relapsed/refractory solid tumors with appropriate dose modifications. Clinical activity was observed in patients with RMS and EWS (clinicaltrials.gov NCT02085148).PMID:37606641 | DOI:10.1158/1078-0432.CCR-23-0257 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - August 22, 2023 Category: Cancer & Oncology Authors: Michela Casanova Francisco Bautista Quentin Campbell Hewson Guy Makin Lynley V Marshall Arnauld C Verschuur Adela Ca ñete Nieto Nadege Corradini Bart A Ploeger Barbara J Brennan Udo Mueller Hong Zebger Gong John W Chung Birgit Geoerger Source Type: research
METTL3-modified lncRNA-MALAT1 regulates the molecular axis of miR-124-3p/CDK4 involved in Ewing's sarcoma
In conclusion, METTL3 promotes tumorigenesis of ES through the MALAT1/miR-124-3p/CDK4 axis.PMID:37605570 | DOI:10.14715/cmb/2023.69.6.29 (Source: Cellular and Molecular Biology)
Source: Cellular and Molecular Biology - August 22, 2023 Category: Molecular Biology Authors: Fangzhou He Tingting Ren Xiaodong Tang Source Type: research
METTL3-modified lncRNA-MALAT1 regulates the molecular axis of miR-124-3p/CDK4 involved in Ewing's sarcoma
In conclusion, METTL3 promotes tumorigenesis of ES through the MALAT1/miR-124-3p/CDK4 axis.PMID:37605570 | DOI:10.14715/cmb/2023.69.6.29 (Source: Mol Biol Cell)
Source: Mol Biol Cell - August 22, 2023 Category: Molecular Biology Authors: Fangzhou He Tingting Ren Xiaodong Tang Source Type: research
METTL3-modified lncRNA-MALAT1 regulates the molecular axis of miR-124-3p/CDK4 involved in Ewing's sarcoma
In conclusion, METTL3 promotes tumorigenesis of ES through the MALAT1/miR-124-3p/CDK4 axis.PMID:37605570 | DOI:10.14715/cmb/2023.69.6.29 (Source: Cellular and Molecular Biology)
Source: Cellular and Molecular Biology - August 22, 2023 Category: Molecular Biology Authors: Fangzhou He Tingting Ren Xiaodong Tang Source Type: research
